BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tabrizian P, Roayaie S, Schwartz ME. Current management of hepatocellular carcinoma. World J Gastroenterol 2014; 20(30): 10223-10237 [PMID: 25132740 DOI: 10.3748/wjg.v20.i30.10223] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 43] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Pinato DJ, Brown MW, Trousil S, Aboagye EO, Beaumont J, Zhang H, Coley HM, Mauri FA, Sharma R. Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma. Br J Cancer 2019;120:512-21. [PMID: 30765873 DOI: 10.1038/s41416-018-0373-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
2 Ho CT, Chang YJ, Yang LX, Wei PL, Liu TZ, Liu JJ. A Novel Microtubule-Disrupting Agent Induces Endoplasmic Reticular Stress-Mediated Cell Death in Human Hepatocellular Carcinoma Cells. PLoS One 2015;10:e0136340. [PMID: 26355599 DOI: 10.1371/journal.pone.0136340] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
3 Kabbach G, Assi HA, Bolotin G, Schuster M, Lee HJ, Tadros M. Hepatobiliary Tumors: Update on Diagnosis and Management. J Clin Transl Hepatol 2015;3:169-81. [PMID: 26623263 DOI: 10.14218/JCTH.2015.00012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
4 Chen L, Guan H, Gu C, Cao Y, Shao J, Wang F. miR-383 inhibits hepatocellular carcinoma cell proliferation via targeting APRIL. Tumor Biol 2016;37:2497-507. [DOI: 10.1007/s13277-015-4071-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
5 Teyateeti A, Mahvash A, Long JP, Abdelsalam ME, Avritscher R, Chasen B, Kaseb AO, Kuban JD, Murthy R, Odisio BC, Teyateeti A, Macapinlac HA, Kappadath SC. Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients. J Hepatocell Carcinoma 2020;7:117-31. [PMID: 32984089 DOI: 10.2147/JHC.S248314] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Liu Y, Zhao JJ, Zhou ZQ, Pan QZ, Zhu Q, Tang Y, Xia JC, Weng DS. IL-37 induces anti-tumor immunity by indirectly promoting dendritic cell recruitment and activation in hepatocellular carcinoma. Cancer Manag Res 2019;11:6691-702. [PMID: 31410060 DOI: 10.2147/CMAR.S200627] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
7 Zhang C, An T, Wang D, Wan G, Zhang M, Wang H, Zhang S, Li R, Yang X, Wang Y. Stepwise pH-responsive nanoparticles containing charge-reversible pullulan-based shells and poly(β-amino ester)/poly(lactic-co-glycolic acid) cores as carriers of anticancer drugs for combination therapy on hepatocellular carcinoma. J Control Release 2016;226:193-204. [PMID: 26896737 DOI: 10.1016/j.jconrel.2016.02.030] [Cited by in Crossref: 75] [Cited by in F6Publishing: 74] [Article Influence: 12.5] [Reference Citation Analysis]
8 Wang Y, Xu Y, Yan W, Han P, Liu J, Gong J, Li D, Ding X, Wang H, Lin Z, Tian D, Liao J. CFIm25 inhibits hepatocellular carcinoma metastasis by suppressing the p38 and JNK/c-Jun signaling pathways. Oncotarget 2018;9:11783-93. [PMID: 29545935 DOI: 10.18632/oncotarget.24364] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
9 Fouad M, El Kassas M, Ahmed E, El Sheemy R. Tumor characteristics of hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C: Comparative analysis with antiviral therapy-naive patients. World J Hepatol 2021; 13(11): 1743-1752 [PMID: 34904042 DOI: 10.4254/wjh.v13.i11.1743] [Reference Citation Analysis]
10 Fanni D, Manchia M, Lai F, Gerosa C, Ambu R, Faa G. Immunohistochemical markers of CYP3A4 and CYP3A7: a new tool towards personalized pharmacotherapy of hepatocellular carcinoma. Eur J Histochem 2016;60:2614. [PMID: 27349315 DOI: 10.4081/ejh.2016.2614] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
11 Kamimura K, Suda T, Yokoo T, Kamimura H, Kanefuji T, Tsuchiya A, Takamura M, Kawai H, Waguri N, Yamagiwa S. Transhepatic arterial infusion chemotherapy using a combination of miriplatin and CDDP powder versus miriplatin alone in the treatment of hepatocellular carcinoma: a randomized controlled trial. BMC Cancer. 2017;17:322. [PMID: 28490356 DOI: 10.1186/s12885-017-3320-7.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Bai N, Peng E, Qiu X, Lyu N, Zhang Z, Tao Y, Li X, Wang Z. circFBLIM1 act as a ceRNA to promote hepatocellular cancer progression by sponging miR-346. J Exp Clin Cancer Res 2018;37:172. [PMID: 30053867 DOI: 10.1186/s13046-018-0838-8] [Cited by in Crossref: 73] [Cited by in F6Publishing: 83] [Article Influence: 18.3] [Reference Citation Analysis]
13 Teyateeti A, Mahvash A, Long J, Abdelsalam M, Avritscher R, Kaseb A, Odisio B, Ravizzini G, Surasi D, Teyateeti A, Macapinlac H, Kappadath SC. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib. World J Gastroenterol 2021; 27(47): 8166-8181 [DOI: 10.3748/wjg.v27.i47.8166] [Reference Citation Analysis]
14 Arsenii N, Piardi T, Diébold MD, Chenard MP, Drame M, De Mestier L, Hoeffel C, Pessaux P, Sommacale D, Thiéfin G. Impact of Visceral Obesity on Microvascular Invasion in Hepatocellular Carcinoma. Cancer Invest 2016;34:271-8. [PMID: 27355681 DOI: 10.1080/07357907.2016.1193747] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
15 Kushner T, Dieterich D, Saberi B. Direct-acting antiviral treatment for patients with hepatocellular carcinoma. Current Opinion in Gastroenterology 2018;34:132-9. [DOI: 10.1097/mog.0000000000000431] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
16 Verger E, Drion P, Meffre G, Bernard C, Duwez L, Lepareur N, Couturier O, Hindré F, Hustinx R, Lacoeuille F. 68Ga and 188Re Starch-Based Microparticles as Theranostic Tool for the Hepatocellular Carcinoma: Radiolabeling and Preliminary In Vivo Rat Studies. PLoS One 2016;11:e0164626. [PMID: 27741267 DOI: 10.1371/journal.pone.0164626] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
17 Anand P, Filipenko P, Huaman J, Lyudmer M, Hossain M, Santamaria C, Huang K, Ogunwobi OO, Holford M. Selective Inhibition of Liver Cancer Cells Using Venom Peptide. Mar Drugs 2019;17:E587. [PMID: 31627357 DOI: 10.3390/md17100587] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
18 Galun D, Basaric D, Zuvela M, Bulajic P, Bogdanovic A, Bidzic N, Milicevic M. Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. World J Hepatol 2015; 7(20): 2274-2291 [PMID: 26380652 DOI: 10.4254/wjh.v7.i20.2274] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
19 Kamimura K, Suda T, Yokoo T, Kamimura H, Kanefuji T, Tsuchiya A, Takamura M, Kawai H, Waguri N, Yamagiwa S, Terai S. Transhepatic arterial infusion chemotherapy using a combination of miriplatin and CDDP powder versus miriplatin alone in the treatment of hepatocellular carcinoma: a randomized controlled trial. BMC Cancer 2017;17:322. [PMID: 28490356 DOI: 10.1186/s12885-017-3320-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
20 Lu H, Han M, Yuan X, Tursun K, Zhang Y, Li Y, Li Z, Feng S, Zhou L, Pan Z, Wang Q, Han K, Liu S, Cheng J. Role of IL-6-mediated expression of NS5ATP9 in autophagy of liver cancer cells. J Cell Physiol 2018;233:9312-9. [PMID: 29227529 DOI: 10.1002/jcp.26343] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
21 Carrillo FJ, Mattos AA, Vianey AF, Vezozzo DC, Marinho F, Souto FJ, Cotrim HP, Coelho HS, Silva I, Garcia JH. Brazilian society of hepatology recommendations for the diagnosis and treatment of hepatocellular carcinoma. Arq Gastroenterol. 2015;52 Suppl 1:2-14. [PMID: 26959803 DOI: 10.1590/s0004-28032015000500001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
22 Fang Z, He L, Jia H, Huang Q, Chen D, Zhang Z. The miR-383-LDHA axis regulates cell proliferation, invasion and glycolysis in hepatocellular cancer. Iran J Basic Med Sci 2017;20:187-92. [PMID: 28293396 DOI: 10.22038/ijbms.2017.8246] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
23 [DOI: 10.1101/518340] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Gong Y, Wu X, Wang T, Zhao J, Liu X, Yao Z, Zhang Q, Jian X. Targeting PEPT1: a novel strategy to improve the antitumor efficacy of doxorubicin in human hepatocellular carcinoma therapy. Oncotarget 2017;8:40454-68. [PMID: 28465466 DOI: 10.18632/oncotarget.17117] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
25 Liu X, Ellens N, Williams E, Burdette EC, Karmarkar P, Weiss CR, Kraitchman D, Bottomley PA. High-resolution intravascular MRI-guided perivascular ultrasound ablation. Magn Reson Med 2020;83:240-53. [PMID: 31402512 DOI: 10.1002/mrm.27932] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
26 Lu J, Wang J, Ling D. Surface Engineering of Nanoparticles for Targeted Delivery to Hepatocellular Carcinoma. Small 2018;14. [PMID: 29251419 DOI: 10.1002/smll.201702037] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 8.0] [Reference Citation Analysis]
27 Chen ZH, Hong YF, Lin J, Li X, Wu DH, Wen JY, Chen J, Ruan DY, Lin Q, Dong M, Wei L, Wang TT, Lin ZX, Ma XK, Wu XY, Xu R. Validation and ranking of seven staging systems of hepatocellular carcinoma. Oncol Lett 2017;14:705-14. [PMID: 28693224 DOI: 10.3892/ol.2017.6222] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
28 Tomizawa M, Shinozaki F, Motoyoshi Y, Sugiyama T, Yamamoto S, Ishige N. Niclosamide suppresses migration of hepatocellular carcinoma cells and downregulates matrix metalloproteinase-9 expression. Oncol Lett 2015;10:3515-8. [PMID: 26788160 DOI: 10.3892/ol.2015.3789] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
29 Fabregat I, Caballero-Díaz D. Transforming Growth Factor-β-Induced Cell Plasticity in Liver Fibrosis and Hepatocarcinogenesis. Front Oncol 2018;8:357. [PMID: 30250825 DOI: 10.3389/fonc.2018.00357] [Cited by in Crossref: 94] [Cited by in F6Publishing: 94] [Article Influence: 23.5] [Reference Citation Analysis]
30 Hu S, Zhu Y, Xia X, Xu X, Chen F, Miao X, Chen X. Ginsenoside Rg3 Prolongs Survival of the Orthotopic Hepatocellular Carcinoma Model by Inducing Apoptosis and Inhibiting Angiogenesis. Anal Cell Pathol (Amst) 2019;2019:3815786. [PMID: 31534898 DOI: 10.1155/2019/3815786] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
31 Marinić J, Broznić D, Milin Č. Preexposure to Olive Oil Polyphenols Extract Increases Oxidative Load and Improves Liver Mass Restoration after Hepatectomy in Mice via Stress-Sensitive Genes. Oxid Med Cell Longev 2016;2016:9191407. [PMID: 26925195 DOI: 10.1155/2016/9191407] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
32 Kuo JR, Shang HS, Ho CT, Lai KG, Liu TZ, Chen YJ, Chiou JF. Cisplatin-induced regulation of signal transduction pathways and transcription factors in p53-mutated subclone variants of hepatoma cells: Potential application for therapeutic targeting. Oncol Lett 2016;12:3723-30. [PMID: 27895723 DOI: 10.3892/ol.2016.5181] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
33 Saberi B, Naik H, Overbey JR, Erwin AL, Anderson KE, Bissell DM, Bonkovsky HL, Phillips JD, Wang B, K Singal A, M McGuire B, Desnick RJ, Balwani M. Hepatocellular Carcinoma in Acute Hepatic Porphyrias: Results from the Longitudinal Study of the U.S. Porphyrias Consortium. Hepatology 2021;73:1736-46. [PMID: 32681675 DOI: 10.1002/hep.31460] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
34 Zhao Q, Zheng B, Meng S, Xu Y, Guo J, Chen LJ, Xiao J, Zhang W, Tan ZR, Tang J, Chen L, Chen Y. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy. Biomed Pharmacother 2019;114:108864. [PMID: 30981107 DOI: 10.1016/j.biopha.2019.108864] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
35 Ho CT, Shang HS, Chang JB, Liu JJ, Liu TZ. Folate deficiency-triggered redox pathways confer drug resistance in hepatocellular carcinoma. Oncotarget. 2015;6:26104-26118. [PMID: 26327128 DOI: 10.18632/oncotarget.4422] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
36 Chagas AL, Mattos AA, Carrilho FJ, Bittencourt PL, Vezozzo DCP, Horvat N, Rocha MS, Alves VAF, Coral GP, Alvares-DA-Silva MR, Barros FMDR, Menezes MR, Monsignore LM, Coelho FF, Silva RFD, Silva RCMA, Boin IFSF, D Albuquerque LAC, Garcia JHP, Felga GEG, Moreira AM, Braghiroli MIFM, Hoff PMG, Mello VB, Dottori MF, Branco TP, Schiavon LL, Costa TFA; Members of the Panel of the 2nd Consensus of the Brazilian Society of Hepatology on the Diagnosis and Management of Hepatocellular Carcinoma. BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA. Arq Gastroenterol 2020;57:1-20. [PMID: 32294682 DOI: 10.1590/S0004-2803.202000000-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
37 Simsek C, Kim A, Ma M, Danis N, Gurakar M, Cameron AM, Philosophe B, Garonzik-Wang J, Ottmann S, Gurakar A, Saberi B. Recurrence of hepatocellular carcinoma following deceased donor liver transplantation: case series. Hepatoma Res 2020;6:11. [PMID: 32582866 DOI: 10.20517/2394-5079.2019.51] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Tabasum S, Noreen A, Maqsood MF, Umar H, Akram N, Nazli Z, Chatha SAS, Zia KM. A review on versatile applications of blends and composites of pullulan with natural and synthetic polymers. International Journal of Biological Macromolecules 2018;120:603-32. [DOI: 10.1016/j.ijbiomac.2018.07.154] [Cited by in Crossref: 51] [Cited by in F6Publishing: 24] [Article Influence: 12.8] [Reference Citation Analysis]
39 Guo W, Zhao L, Wei G, Liu P, Zhang Y, Fu L. Circ_0015756 Aggravates Hepatocellular Carcinoma Development by Regulating FGFR1 via Sponging miR-610. Cancer Manag Res 2020;12:7383-94. [PMID: 32884351 DOI: 10.2147/CMAR.S262231] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
40 Santos LC, Bianchi J, Souza SI, Szutan LA. Hypervascular Lesion in a Cirrhotic Liver: A Case Report. Gastroenterology Res 2014;7:146-8. [PMID: 27785286 DOI: 10.14740/gr630w] [Reference Citation Analysis]
41 Feng XJ, Pan Q, Wang SM, Pan YC, Wang Q, Zhang HH, Zhu MH, Zhang SH. MAP4K4 promotes epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma. Tumour Biol 2016;37:11457-67. [PMID: 27010469 DOI: 10.1007/s13277-016-5022-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
42 Goodwin CR, Yanamadala V, Ruiz-Valls A, Abu-Bonsrah N, Shankar G, Sankey EW, Boone C, Clarke MJ, Bilsky M, Laufer I, Fisher C, Shin JH, Sciubba DM. A Systematic Review of Metastatic Hepatocellular Carcinoma to the Spine. World Neurosurg 2016;91:510-517.e4. [PMID: 27090971 DOI: 10.1016/j.wneu.2016.04.026] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
43 Sim KH, Shu M, Kim S, Kim J, Choi B, Lee YJ. Cilostazol Induces Apoptosis and Inhibits Proliferation of Hepatocellular Carcinoma Cells by Activating AMPK. Biotechnol Bioproc E 2021;26:776-85. [DOI: 10.1007/s12257-021-0002-8] [Reference Citation Analysis]
44 Sun DW, Zhang YY, Sun XD, Chen YG, Qiu W, Ji M, Lv GY. Prognostic value of cytokeratin 19 in hepatocellular carcinoma: A meta-analysis. Clin Chim Acta 2015;448:161-9. [PMID: 26164382 DOI: 10.1016/j.cca.2015.06.027] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
45 Liu SY. Role of exosomes in pathogenesis, progression, diagnosis and treatment of hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2019; 27(5): 330-335 [DOI: 10.11569/wcjd.v27.i5.330] [Reference Citation Analysis]
46 Salman A, Simoneau E, Hassanain M, Chaudhury P, Boucher LM, Valenti D, Cabrera T, Nudo C, Metrakos P. Combined sorafenib and yttrium-90 radioembolization for the treatment of advanced hepatocellular carcinoma. Curr Oncol 2016;23:e472-80. [PMID: 27803608 DOI: 10.3747/co.23.2827] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
47 Weng Qiaoyou, Chen Minjiang, Li Maoquan, Zheng Yong-Fa, Shao Guoliang, Fan Weijun, Xu Xi-Ming, Ji Jiansong. Global microarray profling identifed hsa_ circ_0064428 as a potential immune-associated prognosis biomarker for hepatocellular carcinoma. J Med Genet. 2018;0:1-7. [PMID: 30120213 DOI: 10.1136/jmedgenet-2018-105440] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]